Gene therapy startup Generation Bio has lost no time raising the resources it needs to take its programs forward into the clinic.
With the new financing, Kallyope plans to move its pipeline programs toward the clinic and hire another 16 people.
The French biopharma follows Fosun, Takeda and UCB to become the fourth company to secure a connection to Arix’s stable of startups.
A Celgene spinout known as Celularity with some of the biggest names in biotech and Silicon Valley has raised $250 million for its work in cancer.
BTI will spend the cash on phase 2 trials of a once-failed cancer asset and an old drug repurposed for use in Alzheimer’s and schizophrenia.
Syndesi begins life with a $20.9 million infusion, to carry a SV2A modulator through early proof of concept.
Nebula will enable people to directly, anonymously sell their data to drug developers using a blockchain-enabled peer-to-peer network.
The 30-startup hub will supersede the JLINX incubator J&J helped to set up at its R&D site in Beerse, Belgium.
The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up De Rothschild to invest in 17 firms.
The agreements stand to create investment vehicles with more than $1 billion under management and an interest in bringing British innovation to China.